Adaptive Biotechnologies has seen its fair value estimate climb from $16.00 to $17.14 per share, reflecting a moderate revision upward by market analysts. This change comes as experts weigh Adaptive’s ...

Medical practitioners are constantly updating and refining approaches to prostate cancer care, while new cutting-edge ...

As part of an EU-wide initiative to screen for prostate cancer, researchers in Ireland are studying whether a simple home ...

After screening 72,000 men, researchers found that one death from prostate cancer was prevented for every 456 men who were ...

Dr Ian Walker, executive director of policy at Cancer Research UK, said: “While this long-running study suggests that screening using the PSA test could help reduce deaths from prostate cancer, it ...

Prostate cancer screening for over-50s would save thousands of lives, experts have claimed as the UK decides whether or not ...